Perlara PBC Announces Pharma Collaboration with Novartis

One Bench at a Time

Perlara PBC Announces Pharma Collaboration with Novartis

SAN FRANCISCO, Oct. 19, 2016 /PRNewswire/
Perlara PBC (previously Perlstein Lab PBC) today announced the formation of a drug discovery and development collaboration with Novartis to identify new definitive therapeutics for lysosomal storage disorders, starting with lead program Niemann-Pick Type C Disease. In addition to the collaboration, Novartis has made an equity investment in the company. Financial terms are not disclosed.

“Our expertise in whole-animal phenotypic screens, model organism genetics and automation is complemented by Novartis’ world-class pathway and chemical biology expertise, clinical experience and global leadership,” said Ethan Perlstein, Ph.D., CEO, Perlara PBC. “We are eager to begin this next chapter so that our platform technology and discovery programs can move faster to our goal of helping patients and families impacted by diseases with high unmet need.”

Read More…

News story in C&E News

Upcoming Event

  • A Welcome Party for Newcomers! Location: 953 Indiana Street, San Francisco

    15:30-17:00
    08/31/2018
    Please join us for a celebration to welcome all new companies to the MBC BioLabs family! Come and meet the new faces in the building and enjoy some food!

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter